Open an account

iShares U.S. Pharmaceuticals ETF

IHE · ETF

$102.51−$2.27 (−2.17%)TodayMarket closed ·
Prev close $104.78

About IHE

IHE was created on 2006-05-01 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 1547.92m in AUM and 55 holdings. IHE tracks a broad-based, cap-weighted index of US pharmaceutical companies.

Issuer
iShares
Tracks
DJ US Select / Pharmaceutical
Expense ratio
0.37%
Assets under management
$1.54B
Inception
May 1, 2006
Asset class
Equity
Website
ishares.com

IHE key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
294.83K
Volume
126.01K
Open price
$104.26
High today
$104.26
Low today
$102.02
52 Week high
$108.66
52 Week low
$73.76

iShares U.S. Pharmaceuticals ETF (IHE) at a glance

As of Oct 23, 2026, iShares U.S. Pharmaceuticals ETF (IHE) shares are priced at $102.51, giving the company a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $102.02 and $104.26. The current price is 0.5% above the day's low and 1.7% below its high.

Volume so far is 126.01K shares, below the average of 294.83K shares a day.

Over the past year iShares U.S. Pharmaceuticals ETF has ranged from $73.76 to $108.66, and now sits 82% of the way up that range.

IHE news

  • Stjepan Kalinic

    Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

  • Vandana Singh

    Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

  • Rishabh Mishra

    Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'

  • Chandrima Sanyal

    Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts

  • Chandrima Sanyal

    Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

  • Rishabh Mishra

    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

  • Rishabh Mishra

    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

  • Vishaal Sanjay

    Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.